A5042634861- Animal Virus Infections Studies
- SARS-CoV-2 and COVID-19 Research
- Virus-based gene therapy research
- Viral Infections and Immunology Research
- Hepatitis C virus research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- Herpesvirus Infections and Treatments
- Poxvirus research and outbreaks
- Respiratory viral infections research
- Plant Virus Research Studies
- HIV Research and Treatment
- SARS-CoV-2 detection and testing
- Bacillus and Francisella bacterial research
- Polyomavirus and related diseases
- Hepatitis B Virus Studies
- Virology and Viral Diseases
- Parvovirus B19 Infection Studies
- Long-Term Effects of COVID-19
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Viral Infections and Outbreaks Research
- Cytomegalovirus and herpesvirus research
- Viral Infections and Vectors
- Liver Disease Diagnosis and Treatment
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2025
University of Insubria
2019-2023
Azienda Socio Sanitaria Territoriale Lariana
2021-2023
Center for Prevention and Treatment of Infections
2023
Aziende Socio Sanitarie Territoriale dei Sette Laghi
2021-2022
Ospedale di Circolo e Fondazione Macchi
2021-2022
University of Pisa
2012-2021
National Institute of Allergy and Infectious Diseases
2021
National Institutes of Health
2021
Before April 2022, monkeypox virus infection in humans was seldom reported outside African regions where it is endemic. Currently, cases are occurring worldwide. Transmission, risk factors, clinical presentation, and outcomes of poorly defined.
Although the BNT162b2 COVID-19 vaccine is known to induce IgG neutralizing antibodies in serum protecting against COVID-19, it has not been studied detail whether could generate specific immunity at mucosal sites, which represent primary route of entry SARS-CoV-2.
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma have encouraged research development anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on neutralizing mAbs (or mAb cocktails) that represent late-stage clinical pipeline, i.e., those currently Phase 2 or 3 trials....
Abstract Background Bacterial and fungal superinfections may complicate the course of hospitalized patients with COVID-19. Objectives To identify predictors in Methods Prospective, observational study including COVID-19 consecutively admitted to University Hospital Pisa, Italy, between 4 March 30 April 2020. Clinical data outcomes were registered. Superinfection was defined as a bacterial or infection that occurred ≥48 h after hospital admission. A multivariate analysis performed factors...
ABSTRACT The newly described human metapneumovirus (hMPV) is reported here to be more commonly associated with lower respiratory tract disease. present study examined nasal swab specimens from 90 infants acute infections in Pisa, Italy, over a period of three virus seasons. incidence infection varied each the 3 years, rates positivity for hMPV being 7% 2001 but 37 and 43% 2000 2002, respectively. was noted occur seasonally pattern typical frequency occurrence syncytial virus. More than...
ABSTRACT The natural history and pathogenic potential of the recently identified TT virus (TTV) are currently a matter intensive investigation. In an attempt to shed some light on these issues, nasal blood specimens 1- 24-month-old children hospitalized with clinical diagnosis acute respiratory disease (ARD) were examined for presence, load, genetic characteristics TTV. results have indicated that at least in young children, tract not only represents route by which abundant TTV can be into...
We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This was isolated from patient who had disease treated with these drugs.
Abstract We report an imported case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant P.1 detected in asymptomatic traveler who arrived Italy on indirect flight from Brazil. This shows the risk for introduction SARS-CoV-2 variants flights and need continued surveillance.